Is Connect Biopharma Holdings Ltd (CNTB) Halal?
Shariah Screening — 5 Standards
Based on financial data from December 2024
| Standard | Debt Ratio | Cash Ratio | Receivables | Income | Status |
|---|---|---|---|---|---|
| AAOIFI | 0.1% / 30% | 67.6% / 30% | 0.8% / 30% | 17.11% / 5% | ✗ NOT HALAL |
| DJIM | 0.1% / 33% | 67.6% / 33% | 0.8% / 33% | 17.11% / 5% | ✗ NOT HALAL |
| MSCI | 0.2% / 33% | 92.5% / 33% | 1.0% / 33% | 17.11% / 5% | ✗ NOT HALAL |
| S&P | 0.1% / 33% | 67.6% / 33% | 0.8% / 33% | 17.11% / 5% | ✗ NOT HALAL |
| FTSE | 0.2% / 33% | 92.5% / 33% | 1.0% / 50% | 17.11% / 5% | ✗ NOT HALAL |
Financial Highlights
Profitability
| Gross Margin | 100.0% | |
| Operating Margin | -110481.2% | |
| Net Margin | 0.0% | |
| Return on Equity (ROE) | -66.8% | |
| Return on Assets (ROA) | -38.7% |
Cash Flow & Balance Sheet
| Operating Cash Flow | -$24M |
| Free Cash Flow | -$24M |
| Total Debt | $178,000 |
| Debt-to-Equity | 1.4 |
| Current Ratio | 5.5 |
| Total Assets | $101M |
Price & Trading
| Last Close | $3.69 |
| 50-Day MA | $2.66 |
| 200-Day MA | $2.08 |
| Avg Volume | 101K |
| Beta | -0.2 |
|
52-Week Range
$0.51
| |
About Connect Biopharma Holdings Ltd (CNTB)
Connect Biopharma Holdings Limited, a clinical-stage biopharmaceutical company, engages in the development of therapies for the treatment of inflammatory diseases in the United States. The company's lead product candidate is rademikibart (formerly CBP-201), an antibody designed to target interleukin-4 receptor alpha, which is in Phase 3 studies for the treatment of inflammatory diseases such as atopic dermatitis and asthma. Connect Biopharma Holdings Limited was founded in 2012 and is headquartered in San Diego, California.
Related Halal Stocks in Healthcare
Frequently Asked Questions
Is Connect Biopharma Holdings Ltd (CNTB) halal to invest in?
Based on our screening using AAOIFI Standard 21 (the strictest methodology), Connect Biopharma Holdings Ltd is Not Halal. The company fails one or more screening criteria. We screen against all 5 major standards: AAOIFI, DJIM, MSCI, S&P, and FTSE.
What is Connect Biopharma Holdings Ltd's debt ratio?
Connect Biopharma Holdings Ltd's debt ratio is 0.1% under the AAOIFI standard (which uses market capitalization as the denominator). The AAOIFI threshold is 30%. Under MSCI and FTSE (which use total assets as the denominator), the debt ratio is 0.2%.
What are Connect Biopharma Holdings Ltd's key financial metrics?
Connect Biopharma Holdings Ltd has a market capitalization of $193M, and revenue of $26M. Return on equity stands at -66.8%.
How often is the screening data updated?
Our screening data is updated regularly using the latest available financial statements and market data. Stock prices and market caps are refreshed frequently, while financial statements are updated quarterly when companies report earnings.
Disclaimer: HalalStockGuide.com provides Shariah compliance screening for educational and informational purposes only. This is not a fatwa, financial advice, or a recommendation to buy or sell any security. Screening results are based on publicly available financial data and established methodologies. Always consult a qualified Islamic scholar and a licensed financial advisor before making investment decisions.